Freeline Therapeutics Holdings plc reported earnings results for the nine months ended September 30, 2023. For the nine months, the company reported net loss was USD 26.93 million compared to USD 65.97 million a year ago. Basic loss per share from continuing operations was USD 6.15 compared to USD 17.25 a year ago.
Freeline Therapeutics Holdings plc
Equities
FRLN
US35655L2060
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
-2.67% | 103B | |
+1.80% | 95.28B | |
+1.46% | 22.15B | |
-15.56% | 21.02B | |
-8.58% | 18.15B | |
-41.01% | 16.73B | |
-13.27% | 16.05B | |
+4.61% | 13.68B | |
+34.95% | 12.17B |